Bibliography
- NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352(11):1081-1091.
- BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352(11):1092-1102.
- SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352(11):1071-1080.
- KIMMEL SE, BERLIN JA, KINMAN JL et al.: Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiol. Drug Saf. (2002) 11(2):113-119.
- MCADAM BF, CATELLA-LAWSON F, MARDINI IA et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96(1):272-277.
- CATELLA-LAWSON F, MCADAM B, MORRISON BW et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Therap. (1999) 289(2):735-741.
- TOPPER JN, CAI J, FALB D, GIMBRONE MA JR: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA (1996) 93(19):10417-10422.
- CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296(5567):539-541.
- FURBERG CD, PSATY BD, FITZGERALD GA: Parecoxib, valdecoxib and cardiovascular risk. Circulation (2005) 111(3):249.
- KARIM A, LAURENT A, SLATER ME et al.: A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects. J. Clin. Pharmacol. (2001) 41(10):1111-1119.
- BINGHAM S, BESWICK PJ, BOUNTRA C et al.: The cyclo-oxygenase 2 inhibitor, GW406381X, is effective in animal models of neuropathic pain and central sensitization. J. Pharmacol. Exp. Therap. (2005) 312(3):1161-1169.
Websites
- http://pfizer.com/pfizer/download/news/2005q3_earnfin5.pdf Pfizer, Inc.: Segment/product revenues nine months (2005).
- http://www.rocheusa.com/products/toradol/pi.pdf Roche Pharmaceuticals: Toradol (ketorolac tromethamine) complete product information (Sepetmber, 2002).